collaboration-LIBD collaboration-LIBD Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Update Israel and Gaza conflict Update Israel and Gaza conflict Update on Israel and the Palestine territories
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
India: Many positive developments for the population India: Many positive developments for the population A conversation with interim country manager Sandip Agrawal about a young and growing country
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Digital solutions save lives Digital solutions save lives Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Winners of BVDzero Scholarship Programme Winners of BVDzero Scholarship Programme Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
New production center for Veterinary Public Health New production center for Veterinary Public Health Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Approval for Aservo EquiHaler equine asthma therapy Approval for Aservo EquiHaler equine asthma therapy Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Covid Global Support Programm Covid Global Support Programm COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Genomic Lens Linking Worlds in DNA Genomic Lens Linking Worlds in DNA Adding a new dimension to drug discovery with the help of data science and DNA
How fast can a cheetah run wild and free? How fast can a cheetah run wild and free? Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
InPedILD_trial_enrollment InPedILD_trial_enrollment First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Perceived burden of COPD is higher for younger patients Perceived burden of COPD is higher for younger patients New global survey reveals perceived burden of disease is greater in younger people living with COPD
Award winning employer Award winning employer Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance